메뉴 보기
link 세부 정보
정보 바로가기 : LigaChem's HER2 ADC IKS014 named 'Most Promising ADC to Watch' at World A...
LigaChem's HER2 ADC IKS014 named 'Most Promising ADC to Watch' at World A...[카테고리 설정이 아직되어 있지 않습니다.]
It achieved a 75 percent objective response rate (ORR) in patients with breast cancer who were resistant or intolerant to Enhertu (trastuzumab deruxtecan). LigaChem Bio's Chinese partner, Fosun...
